Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Guillaume Richard-Carpentier, MD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Tapan M. Kadia, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MDMSc, Naveen Pemmaraju, MD, Naval G. Daver, MD, Prithviraj Bose, MD, Sherry A. Pierce, BSN, BA, Samuel Dara, MBBS, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2941.

https://doi.org/10.1182/blood-2019-121784

Published: 2019

Journal Articles

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph + ) acute lymphoblastic leukemia

Farhad Ravandi, Susan O'Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey Jorgensen, Partow Kebriaei, Richard Champlin, Gautam Borthakur, Jan Burger, Alessandra Ferrajoli, Guillermo Garcia-Manero, William Wierda, Jorge Cortes, Hagop Kantarjian

Blood (2010) 116 (12): 2070–2077.

https://doi.org/10.1182/blood-2009-12-261586

Published: 2010

Journal Articles

A Phase 1 Study of Dose-Dense 5-Aza-2′-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).

Guillermo Garcia-Manero, MD, Deborah Thomas, Michael Rytting, M.D., Patrick A. Zweidler-McKay, MD/PhD, Hui Yang, MD, PhD, Zhihong Fang, Shaoqing Kuang, PhD, Samuel Dara, Susan O'Brien, M.D., Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 2030.

https://doi.org/10.1182/blood.V114.22.2030.2030

Published: 2009

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Elias Jabbour, MD, Charles Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., Susan O'Brien

Blood (2009) 114 (22): 2043.

https://doi.org/10.1182/blood.V114.22.2043.2043

Published: 2009

Journal Articles

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Charles A Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, MD, William G. Wierda, M.D., Ph.D, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Susan O'Brien

Blood (2009) 114 (22): 837.

https://doi.org/10.1182/blood.V114.22.837.837

Published: 2009

Journal Articles

Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL)

Stefan Faderl, Deborah A. Thomas, Charles A. Koller, Farhad Ravandi, Jan Burger, Susan O’Brien, Samuel Dara, Hagop M. Kantarjian

Blood (2008) 112 (11): 3960.

https://doi.org/10.1182/blood.V112.11.3960.3960

Published: 2008

Journal Articles

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

Elias Jabbour, Susan O’Brien, Deborah A. Thomas, Stefan Faderl, MD, Charles Asa Koller, MD, Samuel Dara, Rebecca Garris, Jorge Cortes, MD, Hagop M Kantarjian, Farhad Ravandi

Blood (2008) 112 (11): 2919.

https://doi.org/10.1182/blood.V112.11.2919.2919

Published: 2008

Journal Articles

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Farhad Ravandi, MBBS, Deborah Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Samuel Dara, MD, Rebecca Garris, BS, Partow Kebriaei, MD, Gautam Borthakur, MD, William Wierda, MD, PhD, Jan Burger, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2008) 112 (11): 2921.

https://doi.org/10.1182/blood.V112.11.2921.2921

Published: 2008

NARROW

Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph + ) acute lymphoblastic leukemia

A Phase 1 Study of Dose-Dense 5-Aza-2′-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL).

Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL)

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only